252 related articles for article (PubMed ID: 34663639)
1. Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.
Sorrentino C; Ciummo SL; D'Antonio L; Fieni C; Lanuti P; Turdo A; Todaro M; Di Carlo E
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663639
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of interleukin-30 in colon cancer stem cells via CRISPR/Cas9 genome editing inhibits their oncogenicity and improves host survival.
D'Antonio L; Fieni C; Ciummo SL; Vespa S; Lotti L; Sorrentino C; Di Carlo E
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36927528
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-30/IL27p28 Shapes Prostate Cancer Stem-like Cell Behavior and Is Critical for Tumor Onset and Metastasization.
Sorrentino C; Ciummo SL; Cipollone G; Caputo S; Bellone M; Di Carlo E
Cancer Res; 2018 May; 78(10):2654-2668. PubMed ID: 29487200
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-30 subverts prostate cancer-endothelium crosstalk by fostering angiogenesis and activating immunoregulatory and oncogenic signaling pathways.
Ciummo SL; Sorrentino C; Fieni C; Di Carlo E
J Exp Clin Cancer Res; 2023 Dec; 42(1):336. PubMed ID: 38087324
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-30 Promotes Breast Cancer Growth and Progression.
Airoldi I; Cocco C; Sorrentino C; Angelucci D; Di Meo S; Manzoli L; Esposito S; Ribatti D; Bertolotto M; Iezzi L; Natoli C; Di Carlo E
Cancer Res; 2016 Nov; 76(21):6218-6229. PubMed ID: 27550449
[TBL] [Abstract][Full Text] [Related]
7. Hindering triple negative breast cancer progression by targeting endogenous interleukin-30 requires IFNγ signaling.
Sorrentino C; Ciummo SL; D'Antonio L; Lanuti P; Abrams SI; Yin Z; Lu LF; Di Carlo E
Clin Transl Med; 2021 Feb; 11(2):e278. PubMed ID: 33635005
[TBL] [Abstract][Full Text] [Related]
8. The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs.
Ciummo SL; D'Antonio L; Sorrentino C; Fieni C; Lanuti P; Stassi G; Todaro M; Di Carlo E
Front Cell Dev Biol; 2021; 9():689286. PubMed ID: 34195201
[TBL] [Abstract][Full Text] [Related]
9. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
Kim SL; Choi HS; Lee DS
Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
[TBL] [Abstract][Full Text] [Related]
10. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell-derived CHI3L1 activates the MAF/CTLA4 signaling pathway to promote immune escape in triple-negative breast cancer.
Ji S; Yu H; Zhou D; Fan X; Duan Y; Tan Y; Lang M; Shao G
J Transl Med; 2023 Oct; 21(1):721. PubMed ID: 37838657
[TBL] [Abstract][Full Text] [Related]
12. LncRNA XIST regulates breast cancer stem cells by activating proinflammatory IL-6/STAT3 signaling.
Ma Y; Zhu Y; Shang L; Qiu Y; Shen N; Wang J; Adam T; Wei W; Song Q; Li J; Wicha MS; Luo M
Oncogene; 2023 May; 42(18):1419-1437. PubMed ID: 36922677
[TBL] [Abstract][Full Text] [Related]
13. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
[No Abstract] [Full Text] [Related]
14. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
15. Significance of Oct-4 transcription factor as a pivotal therapeutic target for CD44
Sen U; Shanavas S; Nagendra AH; Nihad M; Chaudhury D; Rachamalla HK; Banerjee R; Shenoy P S; Bose B
Cell Biol Int; 2023 Apr; 47(4):742-753. PubMed ID: 36573403
[TBL] [Abstract][Full Text] [Related]
16. Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells.
Wu M; Zhang X; Zhang W; Yan L; Liu X; Zhang M; Pan Y; Lobie PE; Han X; Zhu T
Cell Commun Signal; 2023 Mar; 21(1):59. PubMed ID: 36915147
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
18. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
19. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
20. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
